These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1827018)

  • 1. Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine.
    Saragoça MA; Portela JE; Abreu P; Plavnik F; Vanneta A; Ajzen H; Ramos OL
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):188S-190S. PubMed ID: 1827018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine.
    Saragoça MA; Portela JE; Abreu P; Plavnik F; Ventura R; Vanneta A; Ajzen H; Ramos OL
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S28-30. PubMed ID: 1720481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients.
    Carr AA; Prisant LM
    Am J Hypertens; 1990 Jan; 3(1):8-15. PubMed ID: 2137344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine.
    Saragoça MA; de Almeida JB; Amorim MP; Portela J; Cezaretti ML; Ramos OL
    J Hypertens Suppl; 1989 Dec; 7(6):S288-9. PubMed ID: 2534415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.
    Winer N; Thys-Jacobs S; Kumar R; Davidson WD; Grayson M; Harris C; Walker D; Itskovitz H; Gonasun L
    Clin Pharmacol Ther; 1987 Oct; 42(4):442-8. PubMed ID: 2959426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.
    Staessen J; Lijnen P; Fagard R; Hespel P; Tan WP; Devos P; Amery A
    J Cardiovasc Pharmacol; 1989 Feb; 13(2):271-6. PubMed ID: 2468957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study.
    Mohanty PK; Gonasun LM; Goodman RP; Kirkendal WM; Kontos HA; Samuel P; Wright JT
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):241S-244S. PubMed ID: 2970853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine.
    Welzel D; Burger KJ
    Drugs; 1990; 40 Suppl 2():60-4. PubMed ID: 2150644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-hour ambulatory blood pressure monitoring in the treatment of mild hypertension with isradipine.
    Cihák R; Widimský J; Janský P; Lefflerová K
    Cor Vasa; 1990; 32(2 Suppl 1):54-60. PubMed ID: 2143460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
    Cantor A; Cristal N
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S76-8. PubMed ID: 1695309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of electrocardiographic ischemia in hypertensive patients treated with isradipine or placebo.
    Prisant LM; Carr AA
    J Clin Pharmacol; 1991 Mar; 31(3):233-7. PubMed ID: 1826911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of isradipine in essential hypertension.
    Grossman E; Messerli FH; Oren S; Nunez B; Garavaglia GE
    Am J Cardiol; 1991 Jul; 68(1):65-70. PubMed ID: 1829320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine.
    Török E; Borbás S; Lengyel M; Zorándi A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S79-83. PubMed ID: 1376844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
    Kirch W; Burger KJ; Weidinger G; Welzel D
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S55-9. PubMed ID: 1695304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril.
    Galderisi M; Celentano A; Garofalo M; Tammaro P; Oliviero M; Petrocelli A; de Divitiis O
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):312-6. PubMed ID: 7921533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Welzel D; Burger KJ; Weidinger G
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina].
    Vogt M; Motz W; Strauer BE
    Arzneimittelforschung; 1994 Dec; 44(12):1321-8. PubMed ID: 7848351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isradipine: overall clinical experience in hypertension in the United States.
    Miller H
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S60-4. PubMed ID: 1695305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isradipine, a calcium antagonist, in the control of hypertension following coronary artery-bypass surgery.
    Lawrence CJ; Lestrade A; de Lange S
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):207S-209S. PubMed ID: 1827024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.
    Nelson EB; Pool JL; Taylor AA
    Clin Pharmacol Ther; 1986 Dec; 40(6):694-7. PubMed ID: 2946507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.